top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hGLP1R mice
Strain Name
C57BL/6-Glp1rtm1(GLP1R)Bcgen/Bcgen
Common Name  B-hGLP1R mice
Background C57BL/6 Catalog number  170164
Related Genes 
GLP-1; GLP-1R; GLP-1-R
NCBI Gene ID
14652

mRNA and protein expression analysis

from clipboard


The mRNA of human GLP1R was detectable in the lung of the homozygous B-hGLP1R mice,but not detectable in wildtype mice. While the mouse GLP1R mRNA was not detectable in homozygous B-hGLP1R mice. Also we proved that the protein could be expressed normally by western blot analysis. Human and mouse cross-reactive antibodies were used to detect the GLP1R of the wildtype and humanized GLP1R mice.


Protein expression analysis


from clipboard
IHC for human GLP1R expression. Pancreata from wild-type (+/+) and B-hGLP1R mice (H/H) were stained using an antibody specific for human GLP1R. and only the pancreas from B-hGLP1R mice (H/H) showed hGLP1R positive signal in plasma membrane.

In vivo efficacy of PF-06882961 in B-hGLP1R mice

from clipboard

PF-06882961 improved glucose tolerance and promote insulin secretion in B-hGLP1R mice. B-hGLP1R mice were treated with PF-06882961 for 3 mg/kg, s.c. Then the glucose tolerance test was performed in C57BL/6 and B-hGLP1R mice for 2g/kg D-Glucose is administered by intraperitoneal injection (IPGTT). (A) Blood glucose. (B) Area under the curve (AUC) for IPGTT. (C) Plasma insulin. (D) Area under the curve (AUC) for the plasma insulin. As shown, glucose tolerance was improved by PF-06882961 in B-hGLP1R mice but not in wild-type C57BL/6 mice, and promote plasma insulin secretion in B-hGLP-1R mice. Values are expressed as mean ± SEM. Significance was determined by the Unpaired t test. (*P < 0.05, **P < 0.01, ***P < 0.0001) 


Effect of PF-06882961 and Semaglutide in B-hGLP1R mice food intake

from clipboard

Study of PF-06882961 and Semaglutide in B-hGLP1R mice food intake. B-hGLP1R mice (male, 12-week-old, n=8) were acclimated to handing and oral gavage vehicle for 3 days before study. Mice were grouped by body weight and daily food intake. Subsequently, the mice were treated with dose and route shown in the figure. Food weights were measured on 2.5, 5.5, 15.5 hours after treatment. Values are expressed as mean ± SEM. Significance was determined by the Ordinary one-way ANOVA . (*P < 0.05, **P < 0.01, ***P < 0.0001) 


In vivo efficacy of Semaglutide in HFD induced B-hGLP1R mice

from clipboard

Efficacy study of Semaglutide in HFD induced B-hGLP1R mice. B-hGLP1R mice were fed with a high-fat diet for 12 weeks to induce mice obesity. (A) Body weight change after HFD induction. (B-D) Body weight change after Semaglutide treatment. (E-F) Effect of semaglutide on food intake. 8-10 mice per group. Values are expressed as mean ± SEM. Significance was determined by the Ordinary one-way ANOVA. *p<0.05, **p<0.01,***p<0.001 ,****p<0.0001. 


from clipboard

Efficacy study of Semaglutide in HFD induced B-hGLP1R mice. (A) Blood glucose change after Semaglutide treatment. (B) The glucose tolerance test for 2g/kg D-Glucose is administered by intraperitoneal injection (IPGTT). (C) Area under the curve (AUC) for the IPGTT. 8-10 mice per group. Values are expressed as mean ± SEM. Significance was determined by the Ordinary one-way ANOVA. *p<0.05, **p<0.01,***p<0.001 ,****p<0.0001. 


from clipboard

Efficacy study of Semaglutide in HFD induced B-hGLP1R mice. (A-F) Blood biochemical analysis after treatment. 8-10 mice per group. Values are expressed as mean ± SEM. Significance was determined by the Ordinary one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 


from clipboard

Efficacy study of Semaglutide in HFD induced B-hGLP1R mice.(A) Representative pictures of different groups at termination. (B-D)  Adipose tissue weights after treatment.  (E-G)  Ratios of adipose tissue weight and body weight. 8-10 mice per group. Values are expressed as mean ± SEM. Significance was determined by the Ordinary one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 


Analysis of leukocytes cell subpopulation in B-hGLP1R mice

from clipboard

Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hGLP1R mice (n=3, 9-week-old). Flow cytometry analysis of the splenocytes were performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, monocytes, dendritic cells, granulocytes and macrophages in homozygous B-hGLP1R mice were similar to those in the C57BL/6 mice, demonstrating that GLP1R humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.


from clipboard

Analysis of blood leukocyte subpopulations by FACS. Blood cells were isolated from female C57BL/6 and B-hGLP1R mice (n=3, 9-week-old). Flow cytometry analysis of the blood cells were performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, monocytes, dendritic cells, granulocytes and macrophages in homozygous B-hGLP1R mice were similar to those in the C57BL/6 mice, demonstrating that GLP1R humanized does not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SEM.


from clipboard

Analysis of lymph node leukocyte subpopulations by FACS. Lymph node were isolated from female C57BL/6 and B-hGLP1R mice (n=3, 9-week-old). Flow cytometry analysis of the lymph node were performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells and NK cells in homozygous B-hGLP1R mice were similar to those in the C57BL/6 mice, demonstrating that GLP1R humanized does not change the overall development, differentiation or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.


from clipboard

from clipboard

Analysis of T cell subpopulation in spleen, blood and lymph node. The lymphocytes were isolated from spleen, lymph node and blood in C57BL/6 and B-hGLP1R mice (n=3, 9-week-old). The proportion of T cells subpopulation was tested by flow cytometry. There were no differences between C57BL/6 and B-hGLP1R mice, demonstrating that humanized of GLP1R does not change the overall development, differentiation or distribution of these T cell subtypes. Values are expressed as mean ± SEM.


Blood chemistry of B-hGLP1R mice

from clipboard

Blood chemistry tests of B-hGLP1R mice. Serum from the C57BL/6 and B-hGLP1R mice (n=6, 6-8 week-old) was collected and analyzed for levels of indicators. The measurements of B-hGLP1R mice were similar to that in C57BL/6 mice. Values are expressed as mean ± SEM.